Tag: SMAD4
Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma
Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…
MicroRNA-181a Deficiency Results in Transcriptome-Wide Cell-Specific Changes in The Kidney and Increases Blood Pressure
The micro ribonucleic acid (microRNA) [MiR-181a] is downregulated in the kidneys of rodents and patients suffering from high blood pressure (BP). The miR-181a is a posttranslational inhibitor of renin articulation in vitro, yet pleiotropic systems by which miR-181a may impact BP are unclear. Whether cancellation of miR-181a/b-1 in vivo changes…
IRE combined with toripalimab versus IRE alone for LAPC
Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…
Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing
Possible biomarkers for prognosis and clinical outcomes were identified, through the use whole exome sequencing and RNA sequencing, as therapeutic targets for patients with pancreatic ductal adenocarcinoma (PDAC), according to a recent study. The study, published in Therapeutic Advances in Medical Oncology, also reconfirmed genomic landscapes, major driver mutations, and…
